Packaging
EQUIPPED FOR THE FUTURE OF NASAL DRUG APPLICATION
Friday 29. February 2008 - New research and laboratory tests confirm that the Pfeiffer Unitdose and Bidose systems can make a significant contribution to maximizing drugs effectiveness and minimizing their side effects
Pfeiffer has published a new technical paper on the future of nasal spray systems for dispensing medication. The paper details how technology is meeting the challenge of providing nasal dispensing systems to meet accelerating demand, without compromising safety or performance.
Insights into nasal application
The application of drugs via the nasal route represents a huge pharmaceutical growth area all over the world. Research demonstrates that this dispensing method ensures the respective substance enters the blood quickly and effectively, due to the large surface area, porous endothelial membrane, high total blood flow and the avoidance of first-pass metabolism. This is teamed with extremely high patient convenience levels that cannot be matched by alternatives such as intravenous or other injections. In addition, the current lifestyle drugs market is valued at US$ 23, as more and more people turn to these solutions to impede the symptoms of ageing, and research indicates that the nasal route offers a highly effective means of applying these substances.
100% protection of medication
The latest Pfeiffer laboratory testing programme focuses on the companys Unitdose and Bidose nasal spray devices which have established themselves as market leaders for applications as diverse as anti-migraine and anti-osteoporosis products. Extensive research and development work, spanning several years, partnered by in-house German engineering, has enabled Pfeiffer to produce a nasal spray that is unique in that it protects the contents 100% until they exit the system after actuation. The tests detailed in the new technical paper were carried out by an independent external laboratory* in accordance with ISO 17025 and analysed the protective characteristics and quality of the glass utilised in the devices under severe conditions. The process was geared specifically towards the FDA Guidance for Industry, Container Closure Systems for Packaging Human Drugs and Biologics **, which stipulates that “A container closure system should provide the dosage form with adequate protection from microbial contamination.” Both Pfeiffer products passed all tests, proving their ability to make a significant contribution to the process of maximizing drugs effectiveness and minimizing their side effects.